Agios halts tebapivat LR-MDS after Phase 2b miss; SCD readout due in H2 2026
May 29, 2026, 7:09 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The LR-MDS setback directly reduces the near-term value and potential optionality of tebapivat, likely provoking a stock reaction unless offset by clear upside from the SCD program or alternative catalysts. Historical reactions to pipeline setbacks typically include a declines in valuation multiples and heightened focus on remaining pipeline milestones.
AI summary
What happened, with direct paths to the underlying reporting
Agios disclosed that tebapivat will not be advanced in LR-MDS following a Phase 2b trial that failed to meet the predefined threshold. The drug was well tolerated with no new safety signals, and topline data for tebapivat in sickle cell disease are expected in the second half of 2026. The setback shifts near-term focus to SCD potential and overall pipeline value.
Agios will not advance tebapivat in LR-MDS after Phase 2b misses threshold.
Tebapivat was well tolerated; no new safety signals observed.
Topline data for tebapivat in sickle cell disease expected in H2 2026.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Agios Pharmaceuticals said it will stop development of its sickle cell disease treatment, triggering a roughly 14% premarket drop. The decision raises questions about the rest of…
RISE UP met hemoglobin response: 40.6% vs 2.9%, statistically significant. SCPC reduction trended positive but failed to reach statistical significance. Two key secondary endpoint…
Agios' sickle cell drug hit one primary endpoint but failed on pain crisis reduction. Late-stage miss likely pressures AGIO valuation and approval prospects.
